Core patent strategy for drug development… How to gain an advantage?
As the domestic biopharmaceutical industry moves forward into the global market, responding to patents, which is a prerequisite for challenging original treatments, is being emphasized. In addition to this, new drug development incorporating digital technology and responses to the global development of domestic innovative drugs has become a necessity, not an option. Experts believe that […]
Core patent strategy for drug development… How to gain an advantage?
As the domestic biopharmaceutical industry moves forward into the global market, responding to patents, which is a prerequisite for challenging original treatments, is being emphasized. In addition to this, new drug development incorporating digital technology and responses to the global development of domestic innovative drugs has become a necessity, not an option. Experts believe that […]
Emphasis on IQVIA Bio Korea surprise booth as a biopharmaceutical partner
“I came out to raise awareness of IQVIA and publicize its role as a partner at a time when Korea’s biopharmaceutical industry is growing.” IQVIA Korea, a company specializing in clinical and data development, participated in BIOKOREA 2023 for the first time this year and is actively communicating with the domestic biopharmaceutical industry. As more […]
Surprise booth at IQVIA Bio Korea… Emphasis on biopharma partners
“I came out to raise awareness of IQVIA and publicize its role as a partner at a time when Korea’s biopharmaceutical industry is growing.” IQVIA Korea, a company specializing in clinical and data development, participated in BIOKOREA 2023 for the first time this year and is actively communicating with the domestic biopharmaceutical industry. As more […]
The Land of Opportunity Opened by Biosimilars… K-Bio Pridd
As domestic biosimilar companies stand out in the global market, expectations are rising as to whether they will be able to become a stepping stone for the revitalization of K-Bio. Experts are also paying attention to the value of biosimilars as an element of the bio-industry ecosystem beyond cost savings and benefits for patients. As […]
Genome & Company appoints Hong Yoo-seok, former CEO of GSK
Hong Yoo-seok, the new general manager of Genome & Company Genome & Company, a new microbiome-based drug development company, announced on the 8th that it has appointed Yoo-seok Hong as its general representative. Genome & Company plans to go through the process of appointing Hong Yoo-seok as the new CEO through the regular meeting of […]
Biosimilars are the future power of K-Bio… take your chance now
As financial savings and patient benefits, such as health insurance, emerge as major issues domestically and globally, biosimilars that have the same effect as the original and are cheaper are expanding their presence. In addition, a flood of biosimilars is predicted due to the expiration of patents for major treatments, and endless competition in the […]
AstraZeneca Korea appoints executive director Lim Jae-yoon as head of medical division
AstraZeneca Korea Medicine Department Executive Director Jaeyoon Lim AstraZeneca Korea announced on the 4th that it has appointed Lim Jae-yoon (Country Medical Director) to oversee the medical department. Lim Jae-yoon, Executive Director of the Medical Department of AstraZeneca Korea, joined the Medical Department of AstraZeneca Korea as Oncology therapeutic area Leader in 2019 and contributed […]
The use of saw palmetto drug which is known for urinary dryness is increasing
Amidst the recent trend of increasing patients with benign prostatic hyperplasia due to the aging population, the related treatment market is also exciting. Among them, ‘Saw Palmetto Extract (Serenoa repens)’ is attracting attention again. In the clinical field, it has already been recognized for its therapeutic effect in Europe, etc. According to the pharmaceutical industry […]
Samjin Pharm gets the right to sell Masiten Tablets, a treatment for pulmonary arterial hypertension
Samjin Pharmaceutical announced on the 27th that it had been granted priority sales permission by the Ministry of Food and Drug Safety on the 21st following patent avoidance following a trial decision cited by the Intellectual Property Tribunal for a trial to confirm the scope of a passive right on the 19th for the pulmonary […]
